Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + docetaxel + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of erlotinib (an EGFR tyrosine kinase inhibitor), docetaxel (a taxane), and pemetrexed (an antifolate antineoplastic agent). While each drug has established efficacy in non-small cell lung cancer (NSCLC) treatment, the specific three-drug combination has limited clinical evidence. Erlotinib blocks EGFR signaling, docetaxel disrupts microtubule function, and pemetrexed inhibits folate-dependent enzymes necessary for DNA synthesis.
02
Targets
DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)GART (GAR transformylase)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on erlotinib + docetaxel + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + docetaxel + pemetrexed.